deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02046733

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (STIMULI)

A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy

Sponsor: Bristol-Myers Squibb

Conditions Limited Stage Small Cell Lung Cancer Small Cell Lung Cancer
Interventions Ipilimumab Nivolumab
Updated 17 times since 2017 Last updated: Sep 2, 2024 Started: Dec 18, 2015 Primary completion: May 25, 2020 Completion: Feb 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Limited Stage Small Cell Lung Cancer and Small Cell Lung Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 17 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Nov 2022 · 20 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Unknown → Completed

  3. Sep 2024 — Dec 2024 [monthly]

    Unknown PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  5. Mar 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

▶ Show 12 earlier versions

  1. Nov 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • ETOP IBCSG Partners Foundation
  • Frontier Science Foundation, Hellas
  • Intergroupe Francophone de Cancerologie Thoracique
  • Ludwig Center for Cancer Research of Lausanne
Data source: ETOP IBCSG Partners Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Amsterdam, Netherlands , Avignon, France , Barakaldo, Spain , Barcelona, Spain , Bendigo, Australia , Caen, France , Clamart, France , Clermont-Ferrand, France , Coffs Harbour, Australia and 43 more locations